• Adocia’s partner, Tonghua Dongbao, announced that the primary endpoint of this Phase 1 study has been met and that the results confirmed an accelerated profile of BioChaperone® Lispro compared to lispro.
• Ongoing Phase 3 studies are the only remaining clinical activities before submitting the marketing authorization file to the Chinese regulatory authorities.
• BioChaperone Lispro should be the first insulin in the Ultra-Rapid class marketed in China by a Chinese player.
8:00 a.m. CET – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, today announces new positive results for BioChaperone® Lispro insulin (called THDB0206 in China) with its partner Tonghua Dongbao.
BioChaperone Lispro was compared to Humalog (insulin lispro) and the pharmacokinetics and pharmacodynamics of BioChaperone Lispro were significantly faster. Furthermore, BioChaperone Lispro has confirmed its good tolerance and safety profile.